RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF GEFITINIB DOSE-ESCALATION (500MG/D VERSUS 250MG/D) IN ADVANCED NSCLC PATIENT ACHIEVED STABLE DISEASE (SD) AFTER ONE-MONTH GEFITINIB TREATMENT
- Resource Type
- Journal
- Source
JOURNAL OF THORACIC ONCOLOGY ; NOV 2013, 8 pS1185-pS1185, 1p. Supplement: 2- Subject
- Language
- English
- ISSN
- 15561380